Less controversial alternative to ivermectin could be Regen-Cov


Less controversial alternative to ivermectin could be Regen-Cov

Clinical trial provides the clearest evidence of the therapy’s effectiveness among hospitalised patients

Alistair Smout

Regeneron Pharmaceuticals’s Covid-19 antibody cocktail reduces deaths in hospitalised patients who have not mounted their own antibody response, a large British study published on Wednesday found.

The therapy, Regen-Cov, has been granted emergency use authorisation for people with mild to moderate Covid-19 in the US, but results from the Recovery trial provide the clearest evidence of its effectiveness among hospitalised patients.

It found that the antibody therapy reduced by a fifth the 28-day mortality of people admitted to hospital with Covid-19 whose immune systems had not mounted an antibody response, known as seronegative...

This article is free to read if you register or sign in.

Sunday Times Daily

If you have already registered or subscribed, please sign in to continue.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.

Next Article

Winner, winner chicken dinner: Asian states resort to vaccine bribery

By Juarawee Kittisilpa, Marius Zaharia and Heru Asprihanto
2 min read

Previous Article